Anavex Life Sciences Corp (AVXL) FinancialsAVXLFinancialAnavex Life Sciences Corp

Evaluating the bottom line, Anavex Life Sciences Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -12.80%, provide a clear picture of how effectively AVXL converts its operational activities into shareholder value.

In the context of the broader market, AVXL competes directly with industry leaders such as ALXO and LCTX. With a market capitalization of $298.48M, it holds a leading position in the sector. When comparing efficiency, AVXL's gross margin of N/A stands against ALXO's N/A and LCTX's 100.00%. Such benchmarking helps identify whether Anavex Life Sciences Corp is trading at a premium or discount relative to its financial performance.

The company reported a net income of -5.68 million USD in Q1 2026, but showed a positive turnaround with a net income of 7.82 million USD projected for Q3 2026, indicating potential recovery.